Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fluticasone Furoate

FDA-approved product (spray, metered, nasal), marketed as Arnuity Ellipta, Flonase Sensimist Allergy Relief.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Fluticasone Furoate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Airway obstruction
  • Allergic rhinitis
  • Asthma
  • Chronic obstructive pulmonary disease
  • Nasal congestion
  • Rhinitis, Allergic, Perennial
  • Seasonal allergic rhinitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids; Glucocorticoids
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis40.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fluticasone Furoate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fluticasone Furoate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pharmacovigilance Study to Evaluate Safety of SERETIDE in Participants With Chronic Obstructive Pulmonary Disease (COPD)

    NCT00662805 · start 2004-06

    Registered record
    Registry ID
    NCT00662805
    Conditions
    Pulmonary Disease, Chronic Obstructive
    Interventions
    Salmeterol/Fluticasone propionate
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2004-06
    Completion
    2008-09
    Enrolment
    762

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Disease, Chronic Obstructive
    InterventionSalmeterol/Fluticasone propionate
    PhaseNot recorded
    Registry statusCompleted

  • Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.

    NCT00355342 · start 2004-04-28

    Registered record
    Registry ID
    NCT00355342
    Conditions
    Pulmonary Disease, Chronic Obstructive
    Interventions
    Salmeterol 50 mcg BID; Fluticasone Propionate/Salmeterol 250/50 mcg BID; DISKUS inhaler
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-04-28
    Completion
    2007-09-06
    Enrolment
    186

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Disease, Chronic Obstructive
    InterventionSalmeterol 50 mcg BID; Fluticasone Propionate/Salmeterol 250/50 mcg BID; DISKUS inhaler
    PhasePhase 4
    Registry statusCompleted

  • Pilot Study Comparing Tiotropium (Spiriva) to Salmeterol (Serevent) Plus Fluticasone (Flixotide) in Chronic Obstructive Pulmonary Disease (COPD)

    NCT00239499 · start 2003-09

    Registered record
    Registry ID
    NCT00239499
    Conditions
    Pulmonary Disease, Chronic Obstructive
    Interventions
    Tiotropium; Salmeterol plus Fluticasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-09
    Completion
    2004-08
    Enrolment
    107

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Disease, Chronic Obstructive
    InterventionTiotropium; Salmeterol plus Fluticasone
    PhasePhase 4
    Registry statusCompleted

  • COPD on Primary Care Treatment (COOPT)

    NCT00184977 · start 1998-12

    Registered record
    Registry ID
    NCT00184977
    Conditions
    Pulmonary Disease, Chronic Obstructive; Lung Diseases, Obstructive; Bronchitis, Chronic
    Interventions
    N-acetylcysteine; fluticasone propionate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    1998-12
    Completion
    2003-01
    Enrolment
    270

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Disease, Chronic Obstructive; Lung Diseases, Obstructive; Bronchitis, Chronic
    InterventionN-acetylcysteine; fluticasone propionate
    PhasePhase 4
    Registry statusCompleted

  • Comparison of Two Treatment Regimens in Asthmatic Patients

    NCT01488773 · start 1995-04

    Registered record
    Registry ID
    NCT01488773
    Conditions
    Asthma
    Interventions
    first prescription of montelukast; first prescription of salmeterol
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    1995-04
    Completion
    2006-06
    Enrolment
    132

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    Interventionfirst prescription of montelukast; first prescription of salmeterol
    PhaseNot recorded
    Registry statusCompleted